These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38533429)

  • 1. Harmonising IV Oxycodone with Paediatric Perioperative Medications: A Compatibility Study Through Y-Type Connectors.
    Youssef SH; Garg A; Song Y; Wylie NE; Garg S
    Drug Des Devel Ther; 2024; 18():899-908. PubMed ID: 38533429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simulated Y-Site Compatibility of Vancomycin and Piperacillin-Tazobactam.
    Wade J; Cooper M; Ragan R
    Hosp Pharm; 2015 May; 50(5):376-9. PubMed ID: 26405323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physical compatibility of ceftolozane-tazobactam with selected i.v. drugs during simulated Y-site administration.
    Thabit AK; Hamada Y; Nicolau DP
    Am J Health Syst Pharm; 2017 Jan; 74(1):e47-e54. PubMed ID: 28007721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compatibility of Omadacycline With Select Parenteral Products in Simulated Y-site Administration.
    Butler DA; Moolick K; McCray D; Gifford M
    Clin Ther; 2023 Nov; 45(11):1137-1141. PubMed ID: 37777376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Y-Site Compatibility of Intravenous Levetiracetam With Commonly Used Critical Care Medications.
    Lee TM; Villareal CL; Meyer LM
    Hosp Pharm; 2021 Aug; 56(4):282-286. PubMed ID: 34381262
    [No Abstract]   [Full Text] [Related]  

  • 6. Y-site compatibility of vancomycin and piperacillin/tazobactam at commonly utilized pediatric concentrations.
    Nichols KR; Demarco MW; Vertin MD; Knoderer CA
    Hosp Pharm; 2013 Jan; 48(1):44-7. PubMed ID: 24421422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physical compatibility of isavuconazonium sulfate with select i.v. drugs during simulated Y-site administration.
    So W; Kim L; Thabit AK; Nicolau DP; Kuti JL
    Am J Health Syst Pharm; 2017 Jan; 74(1):e55-e63. PubMed ID: 28007722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physical Compatibility of Medications Used in Critically Ill Patients with Balanced Fluid Solutions.
    Wilder AG; Foushee JA; Fox LM; Navalle J; Wright AM; Greer MA
    Int J Pharm Compd; 2020; 24(3):238-241. PubMed ID: 32401743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Y-site Incompatibility Between Premix Concentrations of Vancomycin and Piperacillin-Tazobactam: Do Current Compatibility Testing Methodologies Tell the Whole Story?
    Kufel WD; Miller CD; Johnson PR; Reid K; Zahra JJ; Seabury RW
    Hosp Pharm; 2017 Feb; 52(2):132-137. PubMed ID: 28321140
    [No Abstract]   [Full Text] [Related]  

  • 10. Compatibility of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, and Piperacillin-Tazobactam with Vancomycin in Dextrose 5% in Water.
    Meyer K; Santarossa M; Danziger LH; Wenzler E
    Hosp Pharm; 2017 Mar; 52(3):221-228. PubMed ID: 28439137
    [No Abstract]   [Full Text] [Related]  

  • 11. Physical compatibility of vancomycin and piperacillin sodium-tazobactam at concentrations typically used during prolonged infusions.
    Leung E; Venkatesan N; Ly SC; Scheetz MH
    Am J Health Syst Pharm; 2013 Jul; 70(13):1163-6. PubMed ID: 23784164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration.
    Avery LM; Chen IH; Reyes S; Nicolau DP; Kuti JL
    Clin Ther; 2019 Oct; 41(10):2162-2170. PubMed ID: 31506218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration.
    Housman ST; Tessier PR; Nicolau DP; Kuti JL
    Am J Health Syst Pharm; 2011 Dec; 68(23):2265-70. PubMed ID: 22095816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
    Asempa TE; Avery LM; Kidd JM; Kuti JL; Nicolau DP
    Am J Health Syst Pharm; 2018 Jul; 75(14):1048-1056. PubMed ID: 29895521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physical compatibility of colistin with analgesics during simulated Y-site administration.
    Dettlaff K; Kowalska A; Gostyńska A
    Am J Health Syst Pharm; 2024 Jun; 81(13):e365-e371. PubMed ID: 38358317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Supporting the use of sildenafil infusions in paediatric and neonatal intensive care - A compatibility study.
    AlSalman F; Howlett M; Breatnach C; Kelly H; O'Brien F
    Eur J Pharm Biopharm; 2020 Jun; 151():153-161. PubMed ID: 32289494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Y-site Injection Physical Compatibility of Remdesivir with Select Intravenous Drugs Used in Palliative Care and for Treating Coronavirus Disease 2019.
    Kondo M; Gempei M; Watanabe K; Yoshida M; Tagui N; Fukao S; Sugaya K; Takase H
    J Nippon Med Sch; 2023 Nov; 90(5):381-386. PubMed ID: 37271548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Compatibility of cefepime and vancomycin during simulated Y-site administration of prolonged infusion.
    Berti AD; Hutson PR; Schulz LT; Webb AP; Rose WE
    Am J Health Syst Pharm; 2015 Mar; 72(5):390-5. PubMed ID: 25694414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration.
    Ruiz VH; Shen Y; Abouelhassan Y; Fouad A; Nicolau DP; Kuti JL
    Am J Health Syst Pharm; 2024 Jan; 81(1):e21-e29. PubMed ID: 37740370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring a case of incompatibility in a complex regimen containing Plasma-Lyte 148 in the pediatric intensive care.
    Nilsson N; Nguyen V; Nezvalova-Henriksen K; Tho I
    Paediatr Anaesth; 2023 Mar; 33(3):211-218. PubMed ID: 36336980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.